BRAIN BIOTECH AG (BNN.DE) Stock Fundamental Analysis

FRA:BNN • DE0005203947

2.54 EUR
+0.01 (+0.4%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Overall BNN gets a fundamental rating of 2 out of 10. We evaluated BNN against 69 industry peers in the Chemicals industry. BNN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BNN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BNN had negative earnings in the past year.
  • In the past year BNN has reported a negative cash flow from operations.
  • BNN had negative earnings in each of the past 5 years.
  • BNN had a negative operating cash flow in each of the past 5 years.
BNN.DE Yearly Net Income VS EBIT VS OCF VS FCFBNN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • BNN has a worse Return On Assets (-17.70%) than 84.06% of its industry peers.
  • Looking at the Return On Equity, with a value of -637.81%, BNN is doing worse than 91.30% of the companies in the same industry.
Industry RankSector Rank
ROA -17.7%
ROE -637.81%
ROIC N/A
ROA(3y)-13.97%
ROA(5y)-11.35%
ROE(3y)-254.67%
ROE(5y)-159.82%
ROIC(3y)N/A
ROIC(5y)N/A
BNN.DE Yearly ROA, ROE, ROICBNN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • BNN's Gross Margin of 57.43% is amongst the best of the industry. BNN outperforms 86.96% of its industry peers.
  • BNN's Gross Margin has been stable in the last couple of years.
  • BNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.36%
BNN.DE Yearly Profit, Operating, Gross MarginsBNN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BNN has about the same amount of shares outstanding.
  • The number of shares outstanding for BNN has been increased compared to 5 years ago.
  • Compared to 1 year ago, BNN has a worse debt to assets ratio.
BNN.DE Yearly Shares OutstandingBNN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
BNN.DE Yearly Total Debt VS Total AssetsBNN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • There is no outstanding debt for BNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.92%
BNN.DE Yearly LT Debt VS Equity VS FCFBNN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • A Current Ratio of 1.42 indicates that BNN should not have too much problems paying its short term obligations.
  • BNN's Current ratio of 1.42 is on the low side compared to the rest of the industry. BNN is outperformed by 69.57% of its industry peers.
  • A Quick Ratio of 0.91 indicates that BNN may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.91, BNN is not doing good in the industry: 63.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 0.91
BNN.DE Yearly Current Assets VS Current LiabilitesBNN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for BNN have decreased by -5.50% in the last year.
  • BNN shows a decrease in Revenue. In the last year, the revenue decreased by -9.52%.
  • The Revenue has been growing slightly by 5.15% on average over the past years.
EPS 1Y (TTM)-5.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.2%
Revenue 1Y (TTM)-9.52%
Revenue growth 3Y-0.05%
Revenue growth 5Y5.15%
Sales Q2Q%-23.53%

3.2 Future

  • The Earnings Per Share is expected to grow by 45.53% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BNN will show a small growth in Revenue. The Revenue will grow by 7.06% on average per year.
EPS Next Y3.78%
EPS Next 2Y68.58%
EPS Next 3Y45.53%
EPS Next 5YN/A
Revenue Next Year12.58%
Revenue Next 2Y11.02%
Revenue Next 3Y8.86%
Revenue Next 5Y7.06%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BNN.DE Yearly Revenue VS EstimatesBNN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
BNN.DE Yearly EPS VS EstimatesBNN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.
  • Also next year BNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNN.DE Price Earnings VS Forward Price EarningsBNN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNN.DE Per share dataBNN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • BNN's earnings are expected to grow with 45.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.58%
EPS Next 3Y45.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BNN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRAIN BIOTECH AG

FRA:BNN (2/27/2026, 7:00:00 PM)

2.54

+0.01 (+0.4%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)01-14
Earnings (Next)02-25
Inst Owners9.2%
Inst Owner ChangeN/A
Ins Owners52.2%
Ins Owner ChangeN/A
Market Cap55.50M
Revenue(TTM)50.22M
Net Income(TTM)-11.74M
Analysts86.67
Price Target5.34 (110.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.67%
PT rev (3m)-6.76%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-126.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.11
P/FCF N/A
P/OCF N/A
P/B 30.15
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS2.3
BVpS0.08
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.7%
ROE -637.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.43%
FCFM N/A
ROA(3y)-13.97%
ROA(5y)-11.35%
ROE(3y)-254.67%
ROE(5y)-159.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.36%
F-Score4
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.33%
Cap/Sales 3.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 0.91
Altman-Z N/A
F-Score4
WACC6.92%
ROIC/WACCN/A
Cap/Depr(3y)41.29%
Cap/Depr(5y)59.09%
Cap/Sales(3y)3.67%
Cap/Sales(5y)5.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.2%
EPS Next Y3.78%
EPS Next 2Y68.58%
EPS Next 3Y45.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.52%
Revenue growth 3Y-0.05%
Revenue growth 5Y5.15%
Sales Q2Q%-23.53%
Revenue Next Year12.58%
Revenue Next 2Y11.02%
Revenue Next 3Y8.86%
Revenue Next 5Y7.06%
EBIT growth 1Y19.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year666.64%
EBIT Next 3Y121.1%
EBIT Next 5YN/A
FCF growth 1Y-104.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.69%
OCF growth 3YN/A
OCF growth 5YN/A

BRAIN BIOTECH AG / BNN.DE FAQ

What is the fundamental rating for BNN stock?

ChartMill assigns a fundamental rating of 2 / 10 to BNN.DE.


What is the valuation status for BNN stock?

ChartMill assigns a valuation rating of 1 / 10 to BRAIN BIOTECH AG (BNN.DE). This can be considered as Overvalued.


How profitable is BRAIN BIOTECH AG (BNN.DE) stock?

BRAIN BIOTECH AG (BNN.DE) has a profitability rating of 1 / 10.


How financially healthy is BRAIN BIOTECH AG?

The financial health rating of BRAIN BIOTECH AG (BNN.DE) is 4 / 10.